Journal
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
Volume 41, Issue 1, Pages 81-91Publisher
SPRINGER
DOI: 10.1007/s11239-015-1313-4
Keywords
Venous thromboembolism; Prevention; Risk factors; Cancer; Direct oral anticoagulants (DOAC); New oral anticoagulants (NOAC)
Funding
- Boehringer Ingelheim
- Daiichi Sankyo
- Janssen Pharmaceuticals
Ask authors/readers for more resources
Venous thromboembolism (VTE) is a highly prevalent complication of malignancy with emerging changes in incidence, diagnosis and treatment paradigms. This manuscript, initiated by the Anticoagulation Forum, provides clinical guidance based on existing guidelines and consensus expert opinion where guidelines are lacking. We address a) the appropriate workup to search for occult malignancy in patients with idiopathic VTE, b) identification of high-risk cancer patients for primary thromboprophylaxis, c) the appropriate immediate and long-term treatment for people with cancer diagnosed with acute thromboembolism, d) the appropriate duration of anticoagulation and e) the appropriate treatment strategy in patients with recurrent VTE on anticoagulation. Areas of controversy and future directions in this field are highlighted.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available